High levels of HLA‐G+ TDEs in peripheral blood samples of breast cancer patients receiving neoadjuvant chemotherapy were also associated with disease progression, whereas high levels of soluble HLA‐G were associated with improved clinical outcomes. This evidence concerns the gene HLA-G and breast cancer.